Prospects of application of non-hormonal drug Femo-Klim in complex therapy of menopausal disorders of medium severity in patients with cancer in anamnesis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study the possibility of using Femo-Klim preparation in the treatment of menopausal disorders of medium severity in gynecologic oncologic patients.

Material and methods. Seventy-eight female patients with menopausal syndrome of moderate severity participated in the study. The patients were randomly divided into 2 groups: the main group (n=40) – patients received Femo-Klim preparation; the comparison group (n=38) – patients did not receive the examined preparation.

Results. After 6 months of the study the dynamics of menopausal manifestations in the main group amounted to -0.9, in the comparison group – -0.7, somatic manifestations – -0.55 and -0.15 respectively, psychoemotional manifestations – -0.8 and -0.5 respectively (p<0.05). The level of anxiety in the main group decreased by 60% compared to the comparison group. Bone mineral density increased by 2.6% in the main group and decreased by 1.4% in the comparison group (p<0.05).

Full Text

Restricted Access

About the authors

O. Vinogradova

Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Author for correspondence.
Email: dge117@mail.ru

Professor, MD

Russian Federation, Penza

O. Biryuchkova

Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: dge117@mail.ru

Associate Professor, Candidate of Medical Sciences

Russian Federation, Penza

S. Mikheeva

Regional Oncological Clinical Dispensary

Email: dge117@mail.ru
Russian Federation, Penza

References

  1. Прожерина Ю., Ильюхина Е. Климактерический синдром: вопросы современной фармакотерапии. Ремедиум. 2018; 11: 41–4 [Prozherina J., Ilyukhina E. Menopausal syndrome: issues of modern pharmacotherapy. Remedium. 2018; 11: 41–4 (in Russ.)].
  2. Якушевская О.В. Альтернативная коррекция климактерических расстройств. Медицинский совет. 2019; 13: 131–6 [Yakushevskaya O.V. Alternative therapies for menopausal disorders. Medical Council. 2019; 13: 131–6 (in Russ.)]. doi: 10.21518/2079-701X-2019-13-131-136
  3. Менопауза и климактерическое состояние у женщины. Клинические рекомендации Минздрава России. 2021; с. 85 [Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Klinicheskie rekomendatsii Minzdrava Rossii. 2021; р. 85 (in Russ.)].
  4. Sabia S., Fournier A., Boutron-Ruault M.-Ch. et al. Risk factors for onset of menopausal symptoms. Results from a large cohort study. Maturitas. 2008; 60 (2): 108–21. doi: 10.1016/j.maturitas.2008.04.004
  5. Green R.A. Measurement of estrogens effects on the brain using modern imaging techniques. Menopausal Med. 1999; 7: 9–12.
  6. Birge S.J. Estrogen and the brain: implications for menopause management. Menopause. Ed. P.G. Schneider. The Parthenon Publishing Group, 2002; pp. 191–5.
  7. Pines A. Vasomotor symptoms and cardiovascular disease risk. Climacteric. 2011; 14: 535–6. doi: 10.3109/13697137.2011.599058
  8. Поворознюк В.В., Григорьева Н.В. Менопауза и костно-мышечная система. Киев: Экспресс, 2004; 512 с. [Povoroznyuk V.V., Grigor'eva N.V. Menopauza i kostno-myshechnaya sistema. Kiev: Ekspress, 2004; 512 р. (in Russ.)].
  9. Струков В.И., Виноградова О.П., Сергеева-Кондраченко М.Ю. и др. Иммунотерапия постменопаузального остеопороза и других заболеваний костно-суставной системы на фоне гормональной недостаточности. Акушерство и гинекология. Новости. Мнения. Обучение. 2022; 10 (2): 47–55 [Strukov V.I., Vinogradova O.P., Sergeeva-Kondrachenko M.Yu. et al. Immunotherapy of postmenopausal osteoporosis and other osteoarticular diseases against the background of hormonal deficiency. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10 (1): 47–55 (in Russ.)]. doi: 10.33029/2303-9698-2022-10-2-47-55
  10. Струков В.И., Елистратов Д.Г., Вихрев Д.В. и др. Диагностика и терапия постменопаузального остеопороза в клинической практике. Врач. 2022; 33 (7): 54–8 [Strukov V., Elistratov D., Vikhrev D. et al. Diagnosis and therapy of postmenopausal osteoporosis in clinical practice. Vrach. 2022; 33 (7): 54–8 (in Russ.)]. doi: 10.29296/25877305-2022-07-10
  11. Abplanalp W., Scheiber M.D., Moon K. et al. Evidence for the role of high density lipoproteins in mediating the antioxidant effect of estrogens. Eur J Endocrinol. 2000; 142 (1): 79–83. doi: 10.1530/eje.0.1420079
  12. Yue W., Santen R., Wang J.-P. et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003; 86 (3–5): 477–86. doi: 10.1016/s0960-0760(03)00377-7
  13. Preston-Martin S., Pike M.C., Ross R.K. et al. Increased cell division as a cause of human cancer. Cancer Res. 1990; 50 (23): 7415–21.
  14. Fishman J. Aromatic hydroxylation of estrogens. Annu Rev Physiol. 1983; 45 (1): 61–72. doi: 10.1146/annurev.ph.45.030183.000425
  15. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021 [Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadovoi. M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2021 (in Russ.)].
  16. Юдина В.С. Злокачественные новообразования органов репродуктивной системы в структуре общей онкологической заболеваемости у лиц в возрасте от 15 до 39 лет в Российской Федерации. Мат-лы VIII Петербургского междунар. онкол. форума «Белые ночи». 2022; с. 170–1 [Yudina V.S. Zlokachestvennye novoobrazovaniya organov reproduktivnoi sistemy v strukture obshchei onkologicheskoi zabolevaemosti u lits v vozraste ot 15 do 39 let v Rossiiskoi Federatsii. Mat-ly VIII Peterburgskogo mezhdunar. onkol. foruma «Belye nochi». 2022; рр. 170–1 (in Russ.)].
  17. Якушевская О.В. Возможности применения фитоэстрогенов в терапии климактерического синдрома. Медицинский совет. 2020; 13: 99–104 [Yakushevskaya O.V. Possibilities of using phytoestrogens in the treatment of menopausal syndrome. Medical Council. 2020; 13: 99–104 (in Russ.)]. doi: 10.21518/2079-701X-2020-13-99-104
  18. Мамонтова А.Г., Усольцева Е.Н. Современный взгляд на альтернативную терапию климактерического синдрома (литературный обзор). Акушерство, гинекология и репродукция. 2018; 12 (2): 39–47 [Mamontova A.G., Usoltseva E.N. Current approaches to alternative therapy in menopausal syndrome (a review). Obstetrics, gynecology and reproduction. 2018; 12 (2): 39–47 (in Russ.)]. doi: 10.17749/23137347.2018.12.2.039-047
  19. Кароматов И.Д., Каххорова С.И. Климакс и лекарственные растения – обзор литературы. Биология и интегративная медицина. 2018; 11: 196–210 [Karomatov I.D., Kakhkhorova S.I. Climax and herbs – the review of literature. Biologiya i integrativnaya meditsina. 2018; 11: 196–210 (in Russ.)].
  20. Сапрыкина Л.В., Нариманова М.Р., Ибрагимова Д.М. Климактерический синдром. Нутрицевтический подход к лечению. РМЖ. Мать и дитя. 2020; 3 (3): 189–93 [Saprykina L.V., Narimanova M.R., Ibragimova D.M. Climacteric syndrome. A nutritional approach to treatment. Russian Journal of Woman and Child Health. 2020; 3 (3): 189–93. (in Russ.)]. doi: 10.32364/2618-8430-2020-3-3-189-193
  21. Якушевская О.В. Негормональная коррекция климактерических расстройств. Медицинский совет. 2021; 21-1: 190–4 [Yakushevskaya O.V. Non-hormonal options for the relief of menopausal disorders. Medical Council. 2021; 21-1: 190–6 (in Russ.)]. doi: 10.21518/2079-701X-2021-21-1-190-196
  22. Beck V., Rohr U., Jungbauer A. Phytoestrogens derived from red clover: An alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol. 2005; 94 (5): 499–518. doi: 10.1016/j.jsbmb.2004.12.038
  23. Oseni T., Patel R., Pyle J. et al. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008; 74 (13): 1656–65. doi: 10.1055/s-0028-1088304
  24. Simoncini T., Fomari L., Mannella P. Activation of nutric oxide synthesis in human endothelial cells by red clover extracts. Menopause. 2005; 1 (1): 69–77. doi: 10.1097/00042192-200512010-00013
  25. Hidalgo L.A., Chedraui P.A. et all. The effect of red clover isoflavones on menopausae symptoms, lipids and vaginal cytology in menopausal women: A randomized, double – blind, placebo – controlled study. Gynecol Endocrinol. 2005; 21 (5): 257–64. doi: 10.1080/09513590500361192
  26. Хабибулина М.М., Шамилов М.Д. Фитоэстрогены («Фемо-Клим») и психологическое состояние при гипоэстрогении и абдоминальном ожирении. Акушерство и гинекология. Новости. Мнения. Обучение. 2022; 10 (3): 107–12 [Khabibulina M.M., Shamilov M.D. Phytoestrogens ("Femo-Klim") and psychological state in women with hypoestrogenism and abdominal obesity. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10 (3): 107–12. (in Russ.)]. doi: 10.33029/2303-9698-2022-10-3-107-112
  27. Хабибулина М.М., Шамилов М.Д. Влияние терапии на уровень тревожности и социальные аспекты жизни женщин с эстрогенодефицитом в период пременопаузы (Фемо-клим). Акушерство и гинекология. Новости. Мнения. Обучение. 2022; 10 (4): 18–22 [Khabibulina M.M., Shamilov M.D. Efficacy of therapy on anxiety and social functioning in premenopausal women with estrogen deficiency. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10 (4): 18–22 (in Russ.)]. doi: 10.33029/2303-9698-2022-10-4-18-22
  28. Елистратов Д.Г., Шамилов М.Д. Улучшение качества жизни при климаксе под влиянием препарата «Фемо-Клим». Медицинская сестра. 2022; 24 (7): 31–5 [Elistratov D.G., Shamilov M.D. Improvement of quality of life in menopause under the influence of Femo-Clim drug. Meditsinskaya sestra. 2022; 24 (7): 31–5 (in Russ.)]. doi: 10.29296/25879979-2022-07-07
  29. Петрова Е.В., Чиж Д.И., Герцог Н.А. и др. Терапевтические подходы в коррекции вазомоторных и психоэмоциональных менопаузальных симптомов. Врач. 2020; 31 (11): 37–44 [Petrova E., Chizh D., Herzog N. et al. Therapeutic approaches to the correction of vasomotor and psychoemotional menopausal symptoms. Vrach. 2020; 31 (11): 37–44 (in Russ.)]. doi: 10.29296/25877305-2020-11-07
  30. Дедов Д.В., Денисова А.Г., Моисеева И.Я. и др. Возможность применения препарата Фемо-Клим у женщин в менопаузе с сердечно-сосудистыми патологиями. Врач. 2023; 34 (8): 75–8 [Dedov D.V., Denisova A. G., Moiseeva I. Ya. et al. Possibility of using Femo-Klim in menopausal women with cardiovascular pathologies. Vrach. 2023; 34 (8): 75–8 (in Russ.)]. doi: 10.29296/25877305-2023-08-14
  31. Виноградова О.П., Бирючкова О.А., Можжухина И.Н. Альтернативные подходы к ведению пациенток с менопаузальными расстройствами. Акушерство и гинекология. Новости. Мнения. Обучение. 2022; 10 (1): 51–9 [Vinogradova O.P., Biryuchkova O.A., Mozhzhukhina I.N. Alternative approaches to clinical management of patients with menopausal disorders. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10 (1): 51–9 (in Russ.)]. doi: 10.33029/2303-9698-2022-10-1-51-59
  32. Kumagai A., Nishino K., Shimomura A. et al. Effect of glycyrrhizin on estrogen action. Endocrinol Japan. 1967; 14 (l): 34–8. doi: 10.1507/endocrj1954.14.34
  33. Mersereau J. E., Levy N., Staub R. E. et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol. 2008; 283 (1–2): 49–57. doi: 10.1016/j.mce.2007.11.020
  34. Toffoletto S., Lanzenberger R., Gingnell M. et al. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. Psychoneuroendocrinology. 2014; 50: 28–52. doi: 10.1016/j.psyneuen.2014.07.025
  35. Kravitz H.M., Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am. 2011; 38 (3): 567–86. doi: 10.1016/j.ogc.2011.06.002
  36. Maskarinec G., Williams A. E., Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev. 2003; 12 (2): 165–9. doi: 10.1097/00008469-200304000-00011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Changes in climacteric, somatic and psychoemotional manifestations of menopausal period

Download (64KB)
Indexing metadata
3. Fig. 2. Changes in the level of anxiety and depression on HADS in the study groups

Download (69KB)
Indexing metadata
4. Fig. 3. Number of nocturnal awakenings in the study groups

Download (72KB)
Indexing metadata
5. Fig. 4. Changes in bone mineral density in the study groups

Download (54KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies